Comparative Pharmacology
Head-to-head clinical analysis: ELDECORT versus HC 1.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELDECORT versus HC 1.
ELDECORT vs HC #1
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid binding to glucocorticoid receptors, leading to anti-inflammatory and immunosuppressive effects via inhibition of phospholipase A2, reduction of prostaglandins and leukotrienes, and modulation of cytokine production.
Unknown
Initial: 5-60 mg orally once daily, adjusted based on response; typical maintenance: 5-15 mg orally once daily.
Hydrocortisone: 100-200 mg IV as initial dose, then 50-100 mg IV every 6 hours, or 0.18 mg/kg/h IV continuous infusion.
None Documented
None Documented
Terminal elimination half-life is 3.5 ± 1.2 hours in adults with normal renal function; prolonged to 6–8 hours in severe renal impairment (CrCl <30 mL/min).
2–4 hours (terminal); prolonged in renal impairment.
Renal excretion of unchanged drug accounts for approximately 60% of the dose; fecal elimination contributes about 30% due to biliary secretion; the remaining 10% is metabolized.
Renal: 90% as unchanged drug; fecal: 10%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid